Recombinant Ligand-Toxin Conjugates, Domain Engineering and the Search for Targeted Pharmaceuticals
Affinity therapy is the opportunity to attempt precise targeting of therapeutic effectors to their site of action. Within the past years, advances in biochemistry and molecular biology of membranes and cell growth regulation have provided tools that can assist in the design of more selective chemotherapeutic agents. Cloning and expressing genes coding for a variety of effector molecules allows the assembly of recombinant chimaeras for anticancer, immunosuppressive, antiviral and cardiovascular targeted therapy (Soria and Zeller, 1978; Soria and Martini, 1987; Soria, 1989a). Site-specific delivery might thus fulfil Paul Ehrlich’s dream of “magic bullets” by engineering specific structural/functional domains into therapeutic agents, in order to improve their persistence in the circulation and to localize them at the site of action.
KeywordsDiphtheria Toxin Sendai Virus Type Plasminogen Activator Vesicular Stomatitis Virus Glycoprotein Diphtheria Toxin Receptor
Unable to display preview. Download preview PDF.
- Gronemeyer, H., 1988, Affinity labelling and cloning of steroid and thyroid hormone receptors: techniques, application and functional analysis, Ellis Horwood, New York.Google Scholar
- Habuka, N., Murakami, Y., Noma, M., Kudo, T. and Horikoshi, K., 1989, Amino acid sequence of Mirabilis antiviral protein, total s5nithesis of its gene and expression in E. coli, J.Biol.Chem., 264:6629.Google Scholar
- Kaneda, Y., Iwai, K. and Uchida, T., 1989a, Introduction and expression of the human insulin gene in adult rat liver, J.Biol.Chem., in press.Google Scholar
- Lorenzetti, R., Benatti, L., Dani, M., Lappi, D.A., Saceardo, B.M. and Soria, M., 1988, Nucleotide sequence encoding plant ribosome- inaetivating protein, Brit, Pat. Appl. n. 880:877.Google Scholar
- Scott, J., 1989, Thrombogenesis linked to atherogenesis at last? Natxire, 341:22.Google Scholar
- Soria, M., 1989a, Molecular targeting and delivery: applications of recombinant DNA technology, Biotechnol.Appl.Biochem., in press.Google Scholar
- Soria, M., 1989b, Immunotoxins, ligand-toxin conjugates and molecular targeting, Pharmacol. Res., in press.Google Scholar
- Soria, M. and Martini, D., 1987, Recombinant strategies in the search for targeted pharmaceuticals, in: Proc. 4th European Congress on Biotechnology, Vol. 4, O.M. Neijssel, R.R. Van der Meer and K.Ch.A.M. Luyben, eds., Elsevier, Amsterdam.Google Scholar
- Soria, M. and Zeller, L., 1978, Expectations and priorities of pharmaceutical industry, in: “Genetic Engineering: Scientific Discoveries and Practical Applications”, H. Boyer and S. Nicosia, eds., Elsevier, Amsterdam.Google Scholar
- Williams, D.P., Parker, K., Bacha, P., Bishai, W., Borowski, M., Genbauffe, F., Strom, T.B. and Murphy, J.R., 1987, Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein, Prot.En, 1:493.CrossRefGoogle Scholar